P300 Latency as a Biomarker for Early Alzheimer's Disease
Author Information
Author(s): Mohamed Manal, Kim Jae Gwan, Nourelhuda Mohamed
Primary Institution: Gwangju Institute of Science and Technology
Hypothesis
Patients in the AAD and PAD stages would have a lower P300 amplitude and a delayed P300 response when processing target information.
Conclusion
The P300 peak latency can effectively differentiate individuals with prodromal AD from asymptomatic AD and healthy controls, but not between asymptomatic AD and healthy controls.
Supporting Evidence
- The P300 peak latency was significantly longer in the PAD group compared to healthy controls.
- Neuropsychological tests showed significant differences in memory tasks between PAD and healthy controls.
- EEG data indicated that P300 indices can serve as biomarkers for early Alzheimer's disease.
Takeaway
This study found that measuring how long it takes for the brain to respond to certain tasks can help tell if someone is in the early stages of Alzheimer's disease.
Methodology
The study used EEG to measure P300 indices during a visual oddball task and compared results among healthy controls, asymptomatic AD, and prodromal AD participants.
Potential Biases
Potential biases due to the small and homogenous sample population.
Limitations
The sample size is relatively small and lacks demographic diversity; results are based on a single cognitive task.
Participant Demographics
79 participants: 35 healthy controls, 22 asymptomatic AD, and 22 prodromal AD, with mean ages of 74.8, 76.5, and 79.6 years respectively.
Statistical Information
P-Value
p < 0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website